Specialty Pharmacy

Thirty two million Americans are affected by migraines, and women are affected 3 times more than men.

Managed care organizations and pharmacy benefit managers are increasingly using strict approaches to manage drugs, including formulary exclusions.

At the 2018 National Community Oncology Dispensing Association (NCODA) Spring Summit, Howard Cohen, RPh, MS, FASHP, from Smilow Cancer Hospital, Yale-New Haven Health, discusses how information technology can be utilized to improve medication adherence on patients with cancer.

Patients treated with erenumab had nearly 3-fold higher odds of having their migraine days cut by at least 50%.

Study finds improving adherence to disease-modifying multiple sclerosis medications could reduce clinical relapses while saving on medical costs.

A review found an elevated risk of cancer progression with increasing wait time between positive screening and start of diagnostic testing.

Top news of the day from across the health care landscape.

Last year, 41% of pharmacy drug spending was for specialty drugs compared with 59% for traditional drugs.

The drive towards value-based care could accelerate through competition among health plans.

Pharmacy benefit manager study indicates that moving patients with hemophilia from standard half-life to extended half-life coagulation factor products carries a significant cost increase.

Nivolumab showed major tumor responses in early stage lung cancer patients and an increase in anti-tumor T-cells that remained after the tumor was removed.

Top news of the day from across the health care landscape.

At the 2018 National Community Oncology Dispensing Association (NCODA) Spring Summit, Ray Bailey, BPharm, RPh, Pharmacists Director at Florida Cancer Specialists, discusses important considerations for managing oral chemotherapy care plans and improving adherence in patients.

With the growing use of digital patient identification to conduct business it comes as no surprise that many people have sought to take advantage of Medicare members.

New treatments for cystic fibrosis, migraines, and multiple sclerosis expected to help push specialty drug costs on the pharmacy benefit to nearly 50% of total drug spending by 2020.

Epidiolex would be the first plant-based cannabinoid approved by the FDA and would create a new category of anti-epileptic drugs.

Christopher W. Kennedy, MSM, Chief Operating Officer, Heritage Biologics, speaks about the positive effects telehealth can have on specialty pharmacy patients.

Top news of the day from across the health care landscape.

Novel technique leverages limited DNA sequences from HIV to spark a priming effect within the patient’s immune response.

The 2019 Benefit and Payment Parameters final rule allows states to select their own Essential Health Benefits benchmark plans.

Top news of the day from across the health care landscape.

The FDA has granted priority review to the application for the treatment of patients with small cell lung cancer whose disease has progressed after 2 or more prior lines of therapy.

New analysis from a phase 3 trial reports that oral, once-daily siponimod (BAF312) consistently reduced disability progression in patients with secondary progressive multiple sclerosis.

Top news of the week from Specialty Pharmacy Times.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Pembrolizumab (Keytruda) met its primary endpoint in the pivotal phase 3 KEYNOTE-042 trial.

Top news of the day from across the health care landscape.

Osimertinib surpassed standard of care with a median progression-free survival of 18.9 months in clinical trials.

HDL cholesterol is known as the good kind, but too much or too little could negatively impact the immune system.

Officials with the FDA have approved fostamatinib disodium hexahydrate (Tavalisse, Rigel) for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment